Coronary Artery Disease Clinical Trial
— FISSTEMIOfficial title:
Primary FIbrinolysis and Secondary STenting Versus immEdiate Stenting in ST-segment Elevation Myocardial Infarction (FISSTEMI)-- A Prospective Randomized Trial of Stent Implantation Strategy After Thrombolytic Therapy
This prospective, multicenter, randomized, controlled, open-label clinical study has a target enrollment of 240 subjects. It will explore whether STEMI patients transferred to a PCI center following thrombolytic therapy and expected to have stent implantation might benefit from an alternative treatment strategy and the use of new technologies designed to improve myocardial protection throughout the medical care process.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | March 2023 |
Est. primary completion date | March 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Inpatients who meet all of the following criteria can be included in the study: 1. Age: 18-75 years old; 2. A confirmed diagnosis of STEMI with symptom onset within 12 h; STEMI criteria: 1. Patient has a history of chest pain/discomfort; 2. ST elevation = 0.1 mV in at least two contiguous leads of an ECG on admission (> 30 minutes; = 0.2 mV required for V2 and V3 ) or the development of new left bundle branch block (LBBB); 3. an increase in cardiac biomarkers (troponin, CK-MB) above the 99th percentile of the laboratory upper reference limit; 3. Time from FMC to wire crossing estimated to be > 120 min; 4. Has a target vessel with TIMI grade 3 flow shown as by CAG and = 50% angiographic stenosis after thrombus aspiration; 5. Has culprit lesions identified as primary lesions; 6. Signed the written informed consent form. Exclusion Criteria: - Patients are not eligible for enrollment if they meet any of the following criteria: 1. A contraindication to thrombolysis; 2. An estimated survival time = 12 months; 3. Known heart failure of Killip class III or above, or mechanical complications such as heart rupture; 4. Known to be participating in any other clinical trial; 5. Pregnant or lactating women, or women experiencing their menstrual period; 6. Weight < 40 Kg or > 125 Kg; 7. Known allergies to drugs that are required during the study such as contrast agents, antiplatelet drugs, and anticoagulants; 8. A target vessel with TIMI grade 0-2 flow as revealed by the initial CAG; 9. Having lesions located in the LMCA or root of the LAD, or with severe multiple vessel disease. |
Country | Name | City | State |
---|---|---|---|
China | The 2nd Affiliated Hospital of Harbin Medical University | Harbin | Heilongjiang |
Lead Sponsor | Collaborator |
---|---|
Harbin Medical University | Tasly Pharmaceuticals, Inc. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | All-cause death | All deaths will be considered to be cardiac deaths unless a clear non-cardiac cause is identified.
Patients will be followed up by telephone or in the clinic at 1, 6, and 12 months after discharge from the hospital to obtain information about all-cause death. |
1, 6, and 12 months | |
Other | New or aggravated heart failure NYHA class IV | Patients with cardiac disease that makes them unable to perform any physical activity without discomfort. Symptoms of heart failure may be present even at rest. If any physical activity is undertaken, discomfort is increased.
Patients will be followed up by telephone or in the clinic at 1, 6, and 12 months after discharge from the hospital to obtain information about new or aggravated heart failure NYHA class IV. |
1, 6, and 12 months | |
Other | Non-fatal re-infarction or revascularization of any acute infarct-related artery | Myocardial infarction related to restenosis: angiographic restenosis = 50% (complex lesions not found) after one stent implantation or balloon angioplasty procedure, accompanied by an elevation and/or decrease of cTn values in the absence of another occlusion.
Patients will be followed up by telephone or in the clinic at 1, 6, and 12 months after discharge from the hospital to obtain information about non-fatal re-infarction or revascularization of any acute infarct-related artery. |
1, 6, and 12 months | |
Other | Cardiogenic shock (1, 6, and 12 months after postoperation) | Cardiogenic shock: systolic blood pressure < 90 mmHg, urine volume < 20 mL/h, clammy skin, cyanosis, tachypnea, and a pulse rate > 100 bpm.
Patients will be followed up by telephone or in the clinic at 1, 6, and 12 months after discharge from the hospital to obtain information about cardiogenic shock. |
1, 6, and 12 months | |
Other | Bleeding complications (classified as GUSTO) | Severe or life-threatening: intracerebral hemorrhage or bleeding that results in substantial hemodynamic compromise requiring treatment;
Moderate: bleeding that requires blood transfusion but does not result in hemodynamic compromise; Mild: bleeding that does not meet above criteria. Patients will be followed up by telephone or in the clinic at 1, 6, and 12 months after discharge from the hospital to obtain information about bleeding complications. |
1, 6, and 12 months | |
Other | Stroke | Stroke is defined as a sudden onset of focal neurological deficits due to cerebrovascular lesions, which lasts > 24 hours. Stroke is caused by ischemic or hemorrhagic cerebrovascular disorders.
Patients will be followed up by telephone or in the clinic at 1, 6, and 12 months after discharge from the hospital to obtain information about stroke. |
1, 6, and 12 months | |
Primary | Complete microvascular perfusion of subepicardial and myocardial tissues-TIMI flow grade 3 | Complete microvascular perfusion of subepicardial and myocardial tissues: TIMI flow grade 3 and TMP grade 3 and complete ST resolution on an ECG at 60 minutes after study intervention (STR = 70%).
For the immediate stenting group, the TIMI flow grade will be evaluated immediately after stent implantation. For the deferred stenting group, the TIMI flow grade will be evaluated after the first and second operations. |
one minute after the end of the each procedure | |
Primary | Complete microvascular perfusion of subepicardial and myocardial tissues-TMP grade 3 | Complete microvascular perfusion of subepicardial and myocardial tissues: TIMI flow grade 3 and TMP grade 3 and complete ST resolution on an ECG at 60 minutes after study intervention (STR = 70%).
For the immediate stenting group, the TMP grade will be evaluated immediately after stent implantation. For the deferred stenting group, the TMP grade will be evaluated after the first and second operations. |
one minute after the end of the each procedure | |
Primary | Complete microvascular perfusion of subepicardial and myocardial tissues-complete ST resolution on an ECG | Complete microvascular perfusion of subepicardial and myocardial tissues: TIMI flow grade 3 and TMP grade 3 and complete ST resolution on an ECG at 60 minutes after study intervention (STR = 70%).
All patients will have an 18-lead ECG within 60 minutes after PCI. |
within 60 minutes after PCI. | |
Secondary | TIMI flow grade for infarct-related arteries | For the immediate stenting group, the TIMI flow grade will be evaluated immediately after stent implantation. For the deferred stenting group, the TIMI flow grade will be evaluated after the first and second operations. | one minute after the end of the each procedure | |
Secondary | TIMI myocardial perfusion (TMP) grade for infarct-related arteries | For the immediate stenting group, the TMPG will be evaluated immediately after stent implantation. For the deferred stenting group, the TMPG will be evaluated after the first and second operations. | one minute after the end of the each procedure | |
Secondary | Measurement of ST resolution on an ECG | All patients will have an 18-lead ECG within 60 minutes after PCI. | 60 minutes after PCI | |
Secondary | TIMI myocardial blush grade (MBG) for infarct-related arteries | For the immediate stenting group, the MBG will be evaluated immediately after stent implantation. For the deferred stenting group, the MBG will be evaluated after the first and second operations. | one minute after the end of the each procedure | |
Secondary | Corrected TIMI frame count (cTFC) for infarct-related arteries | For the immediate stenting group, the cTFC will be evaluated immediately after stent implantation. For the deferred stenting group, the cTFC will be evaluated after the first and second operations. | one minute after the end of the each procedure | |
Secondary | TIMI myocardial perfusion frame count (TMPFC) | All subjects were required to calculate the preoperative and postoperative TMPFC (the delayed group was required to record the TMPFC before and after two operations respectively). | before and after each operation | |
Secondary | Myocardial infarct size | The infarct area will be determined using semi-automatic contortion in the late short-axis enhanced image and will be expressed as a left ventricular mass percentage (%LV).
2. Five to seven days after the first STEMI intervention (prior to discharge after delayed stent implantation), the myocardial infarct size will be recorded. |
five to seven days after the last intervention (prior to discharge) | |
Secondary | Myocardium salvage index (MSI) | MSI refers to the ratio of rescue myocardium to AAR, which is a sensitive method to evaluate the effect of treatment.
Five to seven days after the first STEMI intervention (prior to discharge after delayed stent implantation), the MSI will be recorded. |
five to seven days after the last intervention (prior to discharge) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |